AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

to determine whether a one-time benralizumab (Fasenra, AstraZeneca) injection with and without the current standard of care (prednisolone) is better than prednisolone alone for reducing treatment ...

However, treatment with benralizumab did not result in fewer or less severe dysphagia symptoms than placebo. (Funded by AstraZeneca; MESSINA ClinicalTrials.gov number, NCT04543409.) The trial was ...

In the study, after 28 days of treatment respiratory symptoms were found to be better with benralizumab. After 90 days, there were four times fewer people in the AstraZeneca drug group that failed ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). The FDA has approved an expanded indication of AstraZeneca’s benralizumab ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab ... study was supported by AstraZeneca.

and Fasenra (benralizumab) are positioned for indication expansion into severe asthma and chronic obstructive pulmonary disorder (COPD), respectively, during 2025. Sarin said AstraZeneca’s ...